Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Huperzine A | Vinpocetine | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 50-200 mcg twice daily | 5-20 mg 2-3 times daily (15-60 mg/day total) |
| Timing | Morning and early afternoon. With or without food. | With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours). |
| Cycle Duration | Cycle 2-4 weeks on, 1-2 weeks off to prevent AChE downregulation | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks. |
| Evidence Level | strong_human | moderate_human |
Potent, selective, and reversible inhibitor of acetylcholinesterase (AChE), derived from the club moss Huperzia serrata. Exhibits preference for the tetrameric G4 form of AChE predominant in the mammalian brain. Eight-fold more potent than donepezil and two-fold more potent than rivastigmine at AChE inhibition. Crosses the BBB efficiently. Also antagonizes NMDA receptors at high concentrations and provides neuroprotection via attenuation of oxidative stress, regulation of apoptotic proteins (Bcl-2, Bax, P53, caspase-3), and upregulation of NGF.
50-200 mcg twice daily
Morning and early afternoon. With or without food.
Cycle 2-4 weeks on, 1-2 weeks off to prevent AChE downregulation
Semi-synthetic derivative of vincamine (from Vinca minor/periwinkle) that selectively inhibits phosphodiesterase type 1 (PDE1) in cerebral vasculature, increasing cAMP and cGMP levels to promote vasodilation and restore regional cerebral blood flow without significant systemic blood pressure effects. Reduces intracellular calcium in smooth muscle cells and neurons. Inhibits voltage-gated sodium channels, providing neuroprotection against excitotoxicity. Potent anti-inflammatory agent via direct inhibition of IKK, attenuating NF-kB signaling. Downstream CREB and SRF phosphorylation promotes expression of plasticity-related genes.
5-20 mg 2-3 times daily (15-60 mg/day total)
With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →